Galapagos has discovered new drug targets (human proteins that are starting points
for the development of novel drugs) using human primary cells relevant for rheumatoid arthritis, osteoarthritis and osteoporosis. Galapagos applies these targets to find small molecules that change the activity of these proteins and thereby can influence the course of the disease.

The molecules then form the basis for the development of first-in-class medicines against these bone and joint diseases. This approach is expected to yield a breakthrough in treatment by stopping the disease rather than just treating the symptoms. Pre-clinical development has started on the first rheumatoid arthritis candidate compound, with the aim to initiate a clinical Phase I trial in early 2009.

Additionally, Galapagos has drug discovery programs based on known modes-of-action. The bone metastasis (integrin receptor antagonist) program, acquired through ProSkelia in 2006, is expected to enter Phase I trials in early 2009. Galapagos in-licensed Nanocort®, a liposome formulation of prednisolone, for the treatment of acute rheumatoid arthritis flares and other inflammatory diseases, which has completed Phase I/II trials. Galapagos plans to initiate a Phase II study in 2009.

Through a number of strategic alliances with big pharma, Galapagos has financed expansion of its R&D to more than 30 programs in bone and joint diseases.